5 Best Small Cap Stocks To Own For 2014

Online review sites have become the first place many consumers turn to before making any type of purchase with online review stocks like Angie's List Inc (NASDAQ: ANGI), OpenTable Inc (NASDAQ: OPEN), Yelp Inc (NYSE: YELP) and Tripadvisor Inc (NASDAQ: TRIP) being some of the publicly traded options for investors. But what is the best performing online review stock? First, here are the options to choose from:

Angie's List Inc. More than�2 million members turn to Angie�� List to research, hire, rate and review local service providers in more than�720 categories, like home repair, health care and auto service. Angie's List is scheduled to release fourth quarter and fiscal year 2013 financial results on Wednesday, February 12, after the close of the market. Those results will probably be watched closely as the news wires for Angie�� List is filled with so-called shareholder rights law firms announcing class action suits against the company. The reason? Growing net losses of $52.89M (2012), $49.04M (2011), $27.25M (2010) and $11.98M (2009) don�� inspire much confidence that the company will ever have sustained profitability. Moreover, some of the law firms are�questioning whether Angie's List has derived more than half its revenues from the service providers���meaning its reviews could be dubious.�On Thursday, small cap Angie's List fell 2.61% to $16.77 (ANGI has a 52 week trading range of $11.88�to $28.32 a share) for a market cap of $979.75 million plus the stock is up 31.4% over the past year and up 6.1% since November 2011.

5 Best Small Cap Stocks To Own For 2014: OmniVision Technologies Inc.(OVTI)

OmniVision Technologies, Inc. designs, develops, and markets semiconductor image-sensor devices. The company offers CameraChip image sensors, which are single-chip solutions that integrate various functions, such as image capture, image processing, color processing, signal conversion, and output of a processed image or video stream for use in various consumer and commercial mass-market applications; and CameraCube imaging devices that are image sensors with integrated wafer-level optics. It also provides companion chips used to connect its image sensors to various interfaces, including the universal serial bus and other industry standard interfaces; and companion digital signal processors that perform compression in standardized still photo and digital video formats. In addition, the company designs and develops software drivers for Linux, Mac OS, and Microsoft Windows, as well as for embedded operating systems, such as Blackberry OS, Palm OS, Symbian, Windows CE, Windows Embedded, and Windows Mobile. Its products are used in mobile phones, notebooks, Webcams, digital still and video cameras, commercial and security and surveillance, and automotive and medical applications, as well as in entertainment devices. The company sells its products directly to original equipment manufacturers and value added resellers, as well as indirectly through distributors worldwide. OmniVision Technologies, Inc. was founded in 1995 and is based in Santa Clara, California.

Advisors' Opinion:

• [By Rich Bieglmeier]

  OmniVision Technologies, Inc. (OVTI) plans to release its financial results for the second quarter of fiscal year 2014 on Tuesday, December 03, 2013, shortly after the market closes.� The Company plans to host a conference call to review the results and management's outlook for future periods at 5 p.m. (ET) that day.

5 Best Small Cap Stocks To Own For 2014: FuelCell Energy Inc.(FCEL)

FuelCell Energy, Inc., together with its subsidiaries, engages in the development, manufacturing, and sale of high temperature fuel cells for clean electric power generation primarily in South Korea, the United States, Germany, Canada, and Japan. The company offers proprietary carbonate Direct FuelCell Power Plants that electrochemically produce electricity from hydrocarbon fuels, such as natural gas and biogas. Its fuel cells operate on a range of hydrocarbon fuels, including natural gas, renewable biogas, propane, methanol, coal gas, and coal mine methane. The company also develops carbonate fuel cells, planar solid oxide fuel cell technology, and other fuel cell technologies. It provides its products to universities; manufacturers; mission critical institutions, such as correction facilities and government installations; hotels; and natural gas letdown stations, as well as to customers who use renewable biogas for fuel, including municipal water treatment facilities, br eweries, and food processors. The company was founded in 1969 and is headquartered in Danbury, Connecticut.

Advisors' Opinion:

• [By Richard Stavros]

  I was so scarred by their subsequent crash that when I heard a portfolio manager rhapsodizing about the recent performance of Plug Power Inc (NSDQ: PLUG), Fuelcell Energy Inc (NSDQ: FCEL) and Capstone Turbine Corp (NSDQ: CPST), I could scarcely believe it. These were names that I had not heard in years, names that many investors would like to forget. Indeed, even with the recent run-up in their share prices, the value of these firms today is just a small fraction of what it was back then.

• [By Monica Gerson]

  FuelCell Energy (NASDAQ: FCEL) shares gained 16.79% to $4.59 in the pre-market after the company reported Q1 results. FuelCell posted its quarterly net income of $0.02 per share on revenue of $24.2 million.

• [By Paul Ausick]

  The most heavily traded Nasdaq stocks today are Plug Power Inc. (NASDAQ: PLUG) and FuelCell Energy Inc. (NASDAQ: FCEL). The difference today is that the stock prices are tumbling, with Plug Power down 38.89% at $6.30 in a 52-week range of $0.15 to $11.70 (a new 52-week high today). The company�� stock is worth $0.50 a share according to an analyst at Citron Research, who recently had some very harsh things to say about 3D Systems Inc. (NYSE: DDD) as well. Plug Power�� share volume was nearly 8-times the daily average of around 31 million shares traded.

Hot International Companies To Buy Right Now: OCZ Technology Group Inc(OCZ)

OCZ Technology Group, Inc. designs, develops, manufactures, and distributes computer components for computing devices and systems worldwide. It primarily offers solid state drives, flash memory storage, memory modules, thermal management solutions, AC/DC switching power supply units, and computer gaming solutions. The company?s products are used in industrial equipment and computer systems; computer and computer gaming solutions; mission critical servers and high end workstations; personal computer (PC) upgrades to extend the useable life of existing PCs; high performance computing and scientific computing; video and music editing; home theatre PCs and digital home convergence products; and digital photography and digital image manipulation computers. OCZ Technology Group, Inc. offers its products to retailers, on-line retailers, original equipment manufacturers, systems integrators, and distributors. The company was founded in 2002 and is headquartered in San Jose, Califo rnia.

Advisors' Opinion:

• [By Rich Duprey]

  The not-so-great and wonderful OCZ
  There was no company-specific news that caused solid-state-drive maker OCZ Technology (NASDAQ: OCZ  ) to fall almost 8% Wednesday. But an article that appeared on Seeking Alpha �questioning whether the company had six months or less to live before it filed for bankruptcy seemed to coincide with its fall.

5 Best Small Cap Stocks To Own For 2014: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?

• [By Sean Williams]

  The latest hepatitis-C nightmare came from Achillion Pharmaceuticals (NASDAQ: ACHN  ) which plunged 24% on the week after the FDA placed a clinical hold on its lead compound, sovaprevir (previously known as ACH-1625) because of a worrisome drug-to-drug interaction noted in early stage trials. According to Achillion's update, sovaprevir, when studied with atazanavir, was associated with elevated ALT enzymes in the liver, although no serious adverse events were documented. Even though the FDA is allowing Achillion to continue studying sovaprevir in its mid-stage trial with ACH-3102, it's just another setback for Achillion which is miles behind Gilead Sciences�and AbbVie�in terms of time it will take to bring a new hepatitis-C therapy to market.

• [By Keith Speights]

  2. Achillion Pharmaceuticals (NASDAQ: ACHN  )
  Achillion recently experienced a delay in the game that it had hoped to play. The FDA placed a clinical hold on hepatitis C drug sovaprevir after patients in a phase 1 drug-drug interaction study with the drug combined with ritonavir-boosted atazanavir were found to have elevated liver enzyme levels. Shares dropped 25% in one day as a result.